-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Evolving Standards of Care
-
From Access to Eligibility: What Poland’s Real-World Stage III NSCLC Data Reveal About Treatment Pathways and Health Policy
Dr. Łukasz Kuncman expands on findings from a multicenter Polish study analyzing referral patterns and clinical practice in patients with unresectable stage III NSCLC, emphasizing that access to the modern standard of care depends on a chain of eligibility.
-
Opti-TROP Lung 05 Trial Results Expand First-Line Treatment Options for PD-L1-Positive Advanced NSCLC
Dr. Caicun Zhou indicated that treatment with sac-TMT plus pembrolizumab demonstrated a clinically meaningful PFS benefit and favorable OS trends compared with pembrolizumab monotherapy.
-
Wu-Kong28 Data Support Sunvozertinib as First-Line Treatment Option for EGFR-Mutant NSCLC, Researcher Says
Sunvozertinib demonstrated significantly superior anti-tumor efficacy versus chemotherapy, along with a manageable safety profile and potential long-term survival benefits, according to new data presented by Dr. John V. Heymach.
-
Successive Translations of the Same Target: Highlights from ASCO 2026
In the first half of a two-part editorial, Dr. Gilberto Lopes translates breaking data from several trials that made headlines at ASCO 2026.
-
Toward Durable Disease Control in EGFR-Mutant (mt) NSCLC: Interpreting the Survival Signals from FLAURA2 and MARIPOSA
While the FLAURA2 and MARIPOSA trials represent a defining step toward durable disease control in EGFR mt (+) NSCLC, Drs. Ilit Turgeman and Pasi A. Jänne emphasize that further advances will depend on understanding what persists after an initial response.
-
HARMONi-6 Trial Results Show Consistent OS Benefit Across Key Subgroups
Dr. Shun Lu, who presented the findings during the main plenary session at the 2026 ASCO Annual Meeting, said the results support adopting ivonescimab plus chemotherapy as a potential new standard of care for advanced squamous NSCLC.
-
Asandeutertinib Goes Head-to-Head With Osimertinib in Phase II ESAONA Trial
Interim results from the ESAONA trial, presented by Dr. Yuankai Shi, revealed that asandeutertinib demonstrated significant improvements in iORR and iPFS versus osimertinib for EGFR-mutant NSCLC with brain metastases.
-
Knowing Before We Can Act: The Value of MRD Testing From a Patient’s Perspective
While MRD testing does not eliminate the uncertainty of recurrence, Jan Pezarro explains how advanced molecular testing provides invaluable clarity for patients.
-
What Do Recent ODAC Decisions Mean for Lung Cancer Drug Development and Clinical Trial Design?
In a Q&A with ILCN, Dr. John V. Heymach addresses several rulings from the Oncologic Drugs Advisory Committee and important lessons for research teams.
-
Investigational KRAS G12D Agents Demonstrate Promising Antitumor Activity in Non-Small Cell Lung Cancer
Early findings from two clinical studies support the continued development of setidegrasib and zoldonrasib to target KRAS G12D mutations.